SNY Sanofi American Depositary Shares (Each repstg one-half of one)

44.05
-0.84  -2%
Previous Close 44.89
Open 44.03
Price To Book 1.66
Market Cap 109703357805
Shares 2,490,428,100
Volume 1,346,244
Short Ratio 2.5
Av. Daily Volume 1,261,259

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2019.
BIVV009 Cardinal
Cold agglutinin disease
Phase 3 data due 2H 2019.
BIVV009 Cadenza
Cold agglutinin disease
Phase 1/2 readout due 1H 2019.
BIVV001 (EXTEN-A)
Hemophilia A
FDA Approval announced September 28, 2018.
Cemiplimab
Cutaneous squamous cell carcinoma
Approval announced December 11, 2017.
Admelog (insulin lispro injection)
Diabetes
sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 trial commenced 4Q 2017. Data due 2020.
Efpeglenatide
Type 2 diabetes
Phase 3 trial enrolling.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
PDUFA date under priority review March 11, 2019.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
PDUFA date for sBLA filing April 28, 2019.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial also met primary endpoint - June 9, 2017.
Sotagliflozin
Type 1 Diabetes
Phase 3 data due 1Q 2019.
Isatuximab
Refractory Multiple Myeloma
Phase 3 enrollment commenced November 2016. Data due 2019.
NeoGAA - COMET
Pompe disease
FDA approval announced October 19, 2018.
Dupixent (dupilumab)
Asthma
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 3 enrolling. Data due 2021.
Cemiplimab
Non-small cell lung cancer (NSCLC)
Pivotal Phase 2/3 trial started in July 2016. Data due 2019.
Olipudase alfa
Acid sphingomyelinase deficiency (ASMD)
Data due 2020.
Cemiplimab
Basal cell carcinoma
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis
Phase 3 enrollment commenced 2Q 2017. Data due 2021.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
Phase 3 data released October 16, 2018 - primary and secondary endpoints met.
Dupixent (dupilumab)
Nasal polyps
Phase 2 trial to commence 2018.
Dupixent (dupilumab)
Peanut Allergy
Phase 2 data released May 4, 2017. Phase 3 trial to be initiated 1Q 2018.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
PDUFA date March 22, 2019. Advisory Committee Meeting January 17, 2019.
Sotagliflozin
Type 1 Diabetes
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Phase 3 first read-out expected 2H 2019
Fitusiran (ATLAS)
Hemophilia
Phase 3 trial initiated 4Q 2016. Data due 2019.
Sotagliflozin
Type 2 Diabetes
PDUFA for sBLA January 28, 2019.
Fluzone Quadrivalent (Influenza Vaccine)
Influenza A - children 6-35 months of age.
PDUFA date under priority review May 1, 2019.
Dengvaxia
Dengue
Phase 3 data due 4Q 2018.
Fluzone Quadrivalent (Influenza Vaccine)
Influenza